# Organon & Co. (OGN)

> Organon & Co. (OGN) trades at $13.89 (+0.00%) as of 7:30:06 PM EST on Nov 11, 2026, +0.87% over the past month. Market cap is $3.65B, with 8.5 days to cover in short interest.

Canonical: https://massive.com/quote/ogn
Data as of: 2026-11-12T00:30:06.049Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$13.89** +0.00 (+0.00%)
As of 7:30:06 PM EST on Nov 11, 2026 · 15-minute delayed
NYSE · usd

## Stock performance

How Organon & Co. (OGN) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | +0.00% |
| 1W | +0.43% |
| 1M | +0.87% |
| YTD | +93.72% |
| 1Y | +80.16% |
| 52-wk range | $5.69 – $13.89 |

From daily closes through Nov 11, 2026.

## Key statistics

Today's trading snapshot for OGN: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $13.86 – $13.89 |
| Open | $13.89 |
| Prev close | $13.89 |
| Volume | 1.87M |
| Market cap | $3.65B |
| Shares out | 262.62M |

## Valuation and profitability ratios

Valuation and profitability ratios for Organon & Co.: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | 17.13 |
| P/S | 0.60 |
| P/B | 3.06 |
| P/FCF | 5.40 |
| ROE | 17.8% |
| ROA | 1.6% |
| Debt/Equity | 7.17 |
| Div yield | 0.55% |

As of Nov 10, 2026

## Insider trading

[Organon & Co. (OGN) insider trading](https://massive.com/quote/ogn/insider-trading.md): open-market Form 4 buys and sells by Organon & Co. insiders over the last 12 months.

## 8-K filings

Material corporate events Organon & Co. has disclosed to the SEC on Form 8-K.

- Oct 30, 2026 · Investor presentation
  “To continue this practice, the Company is furnishing certain supplemental non-GAAP metrics for the quarter ended September 30, 2026 that are included in Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.”
- Jul 23, 2026 · [Merger agreement](https://massive.com/quote/sec-filings/8-k/mergers.md)
  “Agreement and Plan of Merger (as it may be amended or supplemented from time to time, the "Merger Agreement"), dated April 26, 2026, by and among the Company, Sun Pharmaceutical Holdings USA, Inc. ("Sun Pharma USA"), and Sun Pharma America, Inc., a wholly owned subsidiary of Sun Pharma USA ("Merger Sub") and, solely for certain specified provisions, Sun Pharmaceutical Industries Limited, Sun Pharma Canada Inc. and Sun Pharma (Netherlands) B.V., pursuant to which Merger Sub will be merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Sun Pharma USA (the "Merger").”
- Jul 17, 2026 · Material litigation
  “On July 6, 2026, a complaint was filed in connection with the Merger in the Superior Court of New Jersey, County of Mercer Chancery Division, against the Company, the current members of the board of directors (the "Board") of the Company, Sun Pharma USA and Merger Sub. The Complaint alleges, among other things, that certain disclosures in the Definitive Proxy Statement filed by the Company in connection with the Merger were materially incomplete and misleading. The Complaint further alleges violations of the New Jersey Uniform Securities Law, N.J. Stat. § 49:3-71, and, under New Jersey common law, negligent misrepresentation and concealment, general negligence, and civil conspiracy.”
- Jun 11, 2026 · Equity compensation grant
  “The stockholders of Organon & Co. approved an amendment and restatement of the Organon & Co. 2021 Incentive Stock Plan... The Amended and Restated 2021 ISP increases the number of shares of the Company's common stock available for issuance thereunder by 8,000,000 shares.”
- Apr 27, 2026 · Executive officer appointment
  “As previously disclosed in a Current Report on Form 8-K filed by the Company on October 27, 2025, on October 26, 2025, Carrie S. Cox was appointed Executive Chair for an interim period. On April 26, 2026, Ms. Cox was appointed to serve as Executive Chair on a non-interim basis.”

## Dividend history and stock splits

Organon & Co.'s recent dividend payments and stock splits.

### Dividends

- $0.02 · ex-div Nov 9, 2026
- $0.02 · ex-div Aug 14, 2026
- $0.02 · ex-div May 11, 2026
- $0.02 · ex-div Feb 23, 2026

### Splits

No recent splits.

## OGN short interest

How heavily OGN is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 8.5 |
| Short interest | 19.69M |
| Avg volume | 2.32M |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## OGN news

The latest news and headlines about Organon & Co. (OGN).

- [Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know](https://www.zacks.com/stock/news/3027082/organon-co-ogn-is-attracting-investor-attention-here-is-what-you-should-know?cid=CS-ZC-FT-fundamental_analysis|most_searched_stocks_v1-3027082) · Zacks Investment Research · Nov 10, 2026 · neutral sentiment
- [Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It](https://www.zacks.com/stock/news/3014658/organon-co-ogn-is-a-trending-stock-facts-to-know-before-betting-on-it?cid=CS-ZC-FT-fundamental_analysis|most_searched_stocks_v1-3014658) · Zacks Investment Research · Oct 26, 2026 · neutral sentiment
- [Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know](https://www.zacks.com/stock/news/3006770/investors-heavily-search-organon-co-ogn-here-is-what-you-need-to-know?cid=CS-ZC-FT-fundamental_analysis|most_searched_stocks_v1-3006770) · Zacks Investment Research · Oct 14, 2026 · neutral sentiment
- [Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock](https://www.zacks.com/stock/news/2999365/here-is-what-to-know-beyond-why-organon-co-ogn-is-a-trending-stock?cid=CS-ZC-FT-fundamental_analysis|most_searched_stocks_v1-2999365) · Zacks Investment Research · Oct 2, 2026 · neutral sentiment
- [BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Apogee Therapeutics, Inc. (Nasdaq – APGE), Simulations Plus, Inc. (Nasdaq – SLP), Roku, Inc. (Nasdaq – ROKU), TruBridge, Inc. (Nasdaq – TBRG)](https://www.globenewswire.com/news-release/2026/06/22/3315553/0/en/BRODSKY-SMITH-SHAREHOLDER-UPDATE-Notifying-Investors-of-the-Following-Investigations-Apogee-Therapeutics-Inc-Nasdaq-APGE-Simulations-Plus-Inc-Nasdaq-SLP-Roku-Inc-Nasdaq-ROKU-TruBri.html) · GlobeNewswire Inc. · Jun 22, 2026 · negative sentiment

## About Organon & Co.

Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.

| Measure | Value |
| --- | --- |
| Exchange | NYSE |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 10K |
| Listed | May 14, 2021 |

[Company website](https://www.organon.com)

## FAQ

### What is the Organon & Co. (OGN) stock price today?

Organon & Co. (OGN) is trading at $13.89 (+0.00% on the day) as of 7:30:06 PM EST on Nov 11, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Organon & Co.?

Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly…

### What is the short interest in OGN?

As of Oct 30, 2026, OGN has 19.69M shares short and 8.5 days to cover.

### Does Organon & Co. (OGN) pay a dividend?

Yes. Organon & Co. (OGN)'s most recent dividend was $0.02 per share, with an ex-dividend date of Nov 9, 2026. Full OGN dividend history is available from the Massive API.

### What exchange is OGN listed on?

Organon & Co. (OGN) trades on NYSE in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time OGN quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=OGN`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Organon & Co. (OGN) insider trading](https://massive.com/quote/ogn/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms